Known Actions of Digoxin
|
|
- Gregory Ramsey
- 5 years ago
- Views:
Transcription
1 Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (<5%, mild inotrope) Neurohormonal effects Vagomimetic action Improves baroreceptor sensitivity Decreases serum norepinephrine concentration Decreases activation of renin-angiotensin system Direct sympathoinhibitory effect Decreases cytokine concentrations Increases release of ANP and BNP Electrophysiological effects S-A node: slowing of the sinus rate independent of vagal influence Atrium: no effect or decreased refractory period AV node: slows conduction Ventricle and Purkinje fibers: practically no electrophysiological effects at low therapeutic doses Toxic/proarrhythmic-- may be caused by calcium-dependent after-potentials Gheorghiade2006 doi: /CIRCULATIONAHA
2 Controversy Ongoing. 210 years later ACC/AHA GUIDELINE 1995 Heart Failure is no longer considered just an edematous state responsive to diuretic therapy Digoxin: Class I, Level of Evidence A Digoxin use in patients with heart failure due to systolic dysfunction not adequately responsive to ACE inhibitors and diuretic drugs Digoxin use in pts with atrial fibrillation and rapid ventricular rates Digoxin is an effective treatment in many patients with moderate to severe heart failure, but there is uncertainty regarding its influence on mortality. JF Williams, et al. JACC (26) 5,
3 DIG TRIAL (NHLBI and DVA) 6800 patients with HFand LVEF 0.45, in sinus rhythm Randomly assignedto digoxin or placebo, double-blind fashion The placebo groupreceiveddiuretics (82%) andace-i (95%) The digoxin group received digoxin, diuretics (81%), and ACE-I (94%). Included 302 centers in the United States and Canada Duration: 31.5 month recruitment, minimum 28 month followup Primary Endpoint: All-causemortality & HospitalizationforHF Ancillary Trial Total of 988 patients with HF and LVEF >0.45 who were randomly assigned to digoxin or placebo Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336: 525
4 DIG TRIAL Primary endpoint CUMULATIVE PROBABILITY OF DEATH OR HOSPITALIZATION DUE TO WORSENING HEART FAILURE Garg R., Gorlin R., Smith T. N Engl J Med 1997; 336:
5 DIG TRIAL All Cause Mortality Heart Failure Mortality p=0.80 p=0.06 Digitalis Investigation Group. N Engl J Med. 1997; 336: 525
6 DIG TRIAL Cumulative Probability of Death or Hospitalization due to Heart Failure Hospitalization for worsening HF (P<0.001) Death caused by worsening HF (P=0.06) Benefits were incremental to use of diuretic and ACE-inhibitors Digitalis Investigation Group. N Engl J Med. 1997; 336: 525
7 DIG TRIAL HF-rEF High Risk pre-specified subgroup analysis NYHA class III IV LVEF < 25 % CTR > 55 % Gheorghiade M, et al. European Journal of Heart Failure 2013; 15: DOI: /eurjhf/hft010
8 Controversy Over!?. 216 years later ACC/AHA GUIDELINES 2001 Digoxin: Class I, Level of Evidence A Digitalis is recommended for the treatment of symptoms of HF (NYHA classes II-IV) in patients with LV systolic dysfunction, unless contraindicated. Not for Asx HF-rEF pts in SR. II A (A). Digitalis to control the ventricular response in patients with HF and atrial fibrillation. II B (C). Digitalis to minimize symptoms of HF in patients with HF-pEF Hunt, SA et al ACC/AHA Heart Failure Guideline
9
10 Pharmacological Treatment for Stage C HF With Reduced EF Ivabradine COR LOE Recommendations IIa B-R Ivabradine can be beneficial to reduce HF hospitalization for patients with symptomatic (NYHA class II-III) stable chronic HFrEF (LVEF 35%) who are receiving GDEM*, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of 70 bpm or greater at rest. Comment/ Rationale NEW: New clinical trial data. *In other parts of the document, the term GDMT has been used to denote guideline-directed management and therapy. In this recommendation, however, the term GDEM has been used to denote this same concept in order to reflect the original wording of the recommendation that initially appeared in the 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure.
11 Yancy CW et al ACC/AHA Heart Failure Guideline Controversy Over!. 230 years hence! ACC/AHA GUIDELINES Digoxin: Class IIa, Level of Evidence: B Digoxin can be beneficial in patients with HF-rEF, unless contraindicated, to decrease hospitalizations for HF. Therapy with digoxin is commonly initiated and maintained at a dose of to 0.25 mg daily. Low doses (0.125 mg daily or every other day) should be used initially if the patient is >70 years of age, has impaired renal function, or has a low lean body mass. There is no reason to use loading doses of digoxin to initiate therapy in patients with HF. Doses of digoxin that achieve a plasma concentration of drug in the range of 0.5 to 0.9 ng/ml are suggested, given the limited evidence currently available
12 2014 AHA/ACC/HRS atrial Fibrillation Guidelines Recommendations In the absence of pre-excitation, intravenous digoxin or amiodarone is recommended to control heart rate acutely in patients with HF. Digoxin is effective to control resting heart rate in patients with HF with reduced EF. Class I LOE: B Class I LOE: C Class I LOE: B Class I LOE: C January C.T., et al. J Am Coll Cardiol. 2014; 64(21): Fuster V., et al. J Am Coll Cardiol. 2006; 48(4):
13 Timeline: enthusiasm for DIGOXIN 1993 PROVED 1993 RADIANCE AHA/ACC TREATMENT GUIDELINES 1997 DIG 2002 AFFIRM 2006 DIG post-hoc AFFIRM post-hoc 2014 TREAT-AF
14 A NEVER - ENDING STORY? Digoxin Reduces 30-day All-cause Hospital Admission in Older Patients with Chronic Systolic Heart Failure n = 3405 Age 65 years (mean age, 72 yr) 25% women; 11% nonwhite Bourge, R et al. Am J Med. 2013; 126(8): doi: /j.amjmed
15 WHY WON T DIG WHITHER? Clinical Significance! According to the new United States health care reform law, starting October 2012, hospitals are being penalized for higher than expected 30-day all-cause hospital readmissions for older patients with heart failure. We have limited therapies for patients with advanced heart failure In these patients we are frequently reducing or withdrawing efficacious therapies due to intolerance, renal dysfunction Reducing or stopping ACE/ARB and Beta Blockers reflects very high risk patients Bourge, R et al. Am J Med. 2013; 126(8): doi: /j.amjmed
16 Resting Heart Rate and CV Outcomes in Patients with HF Retrospective analysis of 7,599 symptomatic HF* patients from the CHARM studies, who were followed for a median of 38 months to determine the relationship between resting heart rate at baseline and all-cause mortality, and fatal and nonfatal CV outcomes. Tertile 1: Median heart rate 60 bpm Tertile 2: Median heart rate 72 bpm Tertile 3: Median heart rate 85 bpm 0.4 All-Cause Mortality p< CV Death or WHFH p<0.001 Probability Months Months Heart rate is an important predictor of mortality and CV outcomes in patients with HF WHFH = worsening heart failure hospitalization; *symptomatic HF defined as NYHA functional Class II to IV. Adapted from: Castagno D, et al. J Am Coll Cardiol. 2012;59:
17 Ivabradine Specific inhibitor of the I f current in SA node This so-called funny current controls the rate of spontaneous activity of SA node myocytes Reduces the slope for diastolic depolarization Prolongs diastolic duration à slows heart rate No action on other cardiac channels Does not modify cardiac contractility DiFrancesco D. Pharmacol Res. 2006;53(5): Savelieva I, Camm AJ. Drug Saf. 2008;31(2):
18 Objective of the SHIFT Study To evaluate whether the I f inhibitor ivabradine improves cardiovascular outcomes in patients with: 1. Moderate to severe chronic HF 2. Left ventricular EF 35% 3. Heart rate 70 bpm, and 4. Recommended therapy Swedberg K, et al. Lancet. 2010;376:
19 Inclusion Criteria: SHIFT Study: Design 18 years; symptomatic HF NYHA Class II to IV; ischemic/non-ischemic etiology LV systolic dysfunction (EF 35%); heart rate 70 bpm; sinus rhythm Documented hospital admission for worsening HF 12 months Ivabradine 5 mg bid, titrate to 7.5 mg bid on D14, adjust dose to 7.5/5/2.5 mg bid according HR and tolerability n=3241 D 0 D 14 7,411 Screened HF Patients (n=6,558) R Median follow-up 22.9 months n=3264 D 0 D 14 Placebo bid Primary endpoint: CV death or hospitalization for worsening HF Swedberg K, et al. Lancet. 2010;376:
20 SHIFT Study: Baseline Characteristics Ivabradine (n=3241) Placebo (n=3264) Mean heart rate (bpm) Mean LVEF (%) 29.0% 29.0% NYHA Class II /III (%) 49%/ 50% 49%/ 50% Mean SBP, mm Hg egfr, ml/min/1.73 m Beta-blocker (%) 89% 90% ACE inhibitor/arb (%) 79%/ 14% 78%/ 14% Diuretics (%) 84% 83% Aldosterone antagonist (%) 61% 59% Digitalis (%) 22% 22% CRT/ ICD (%) 1%/ 3% 1%/ 4% Swedberg K, et al. Lancet. 2010;376:
21 Background Beta-Blocker Treatment Ivabradine Placebo 70 Patients (%) BB at Randomization At Least 50% Target Daily Dose Target Daily Dose Swedberg K, et al. Lancet. 2010;376:
22 SHIFT Study: Primary Endpoint of CV Death or Hospitalization for Worsening HF 40 Ivabradine (n=3241) Patients with Primary Endpoint (%) Placebo (n=3264) Placebo 937 events (29%) Ivabradine 793 events (24%) 18% 0 HR 0.82 (95% CI, ) p< ARR = 5%, NNT = Months Swedberg K, et al. Lancet. 2010;376:
23 SHIFT Study: Mean Heart Rate Mean ivabradine dose was 6.4 mg bid at 1 month and 6.5 mg bid at 1 year 90 Ivabradine Placebo Heart Rate (bpm) HR reduction: Ivabradine HR 10.9 bpm at day 28, 9.1 bpm at 1 year, and 8.1 at study end vs. placebo. 0 2 weeks Months Swedberg K, et al. Lancet. 2010;376:
24 SHIFT Study: Cardiovascular Death 30 Ivabradine Placebo Patients with Event (%) Placebo 491 events (15%) Ivabradine 449 events (14%) 0 HR 0.91, p= Months Swedberg K, et al. Lancet. 2010;376:
25 SHIFT Study: Hospitalization for Worsening HF Patients with First Hospitalization for Worsening HF (%) Ivabradine Placebo Placebo 672 events (21%) HR 0.74 (95% CI, ) p< NNT = Months Ivabradine 514 events (16%) 26% Swedberg K, et al. Lancet. 2010;376:
26 SHIFT Study: Effect of Ivabradine on Outcomes Endpoint Ivabradine (n=3241) Placebo (n=3264) HR p-value Primary endpoint 24% 29% 0.82 < All-cause mortality 16% 17% Death from HF 3% 5% All-cause hospitalization 38% 42% Any CV hospitalization 30% 34% CV death, hospitalization for worsening HF, or hospitalization for non-fatal MI 25% 30% 0.82 < Swedberg K, et al. Lancet. 2010;376:
27 SHIFT Study: Effect of Ivabradine in Prespecified Subgroups Age <65 years 65 years Sex Male Female Beta-blockers No Yes Aetiology of heart failure Non-ischaemic Ischaemic NYHA Class NYHA Class II NYHA Class III or IV Diabetes No Yes Hypertension No Yes Baseline heart rate <77 bpm 77 bpm Test for Interaction p=0.099 p=0.260 p=0.103 p=0.059 p=0.793 p=0.861 p=0.779 p=0.029 Swedberg K, et al. Lancet. 2010;376: Hazard Ratio Favors Ivabradine Favors Placebo 1.5
28 SHIFT Study: Effect of Ivabradine in Patients at 50% BB Target Dose (n=3181) Ivabradine Placebo Hazard Ratio p-value Primary composite endpoint 330 (11.9 PY) 362 (13.3 PY) 0.90 ns Cardiovascular death 176 (5.9 PY) 175 (5.9 PY) 1.00 ns Hospitalization for worsening HF 213 (7.7 PY) 260 (9.6 PY) 0.81 p= Favors Ivabradine 1.0 Hazard Ratio Favors Placebo 1.5 Swedberg K, et al. J Am Coll Cardiol. 2012;59(22):
29 SHIFT Study: Effect on Recurrence of Hospitalizations for Worsening HF Ivabradine (n=3241) Placebo (n=3264) Hazard Ratio p-value First hospitalization 514 (16%) 672 (21%) 0.75 p<0.001 Second hospitalization 189 (6%) 283 (9%) 0.66 p<0.001 Third hospitalization 90 (3%) 128 (4%) 0.71 p= Favors Ivabradine 1.0 Hazard Ratio 1.2 Favors Placebo Broer JS, et al. Eur Heart J. 2012;33(22):
30 SHIFT Study: Incidence of Selected Adverse Events Endpoint Ivabradine (n=3241) Placebo (n=3264) p-value All serious adverse events 45% (1450) 48% (1553) All adverse events 75% (2439) 74% (2423) Heart failure 25% (804) 29% (937) Symptomatic bradycardia 5% (150) 1% (32) < Asymptomatic bradycardia 6% (184) 1% (48) < Atrial fibrillation 9% (306) 8% (251) Phosphenes 3% (89) 1% (17) < Blurred vision 1% (17) <1% (7) Phosphenes are luminous phenomena; bradycardia is defined here as resting heart rate was lower than 50 bpm or the patient had signs or symptoms related to bradycardia. Swedberg K, et al. Lancet. 2010;376:
31 Effect of Ivabradine on Outcomes according to HR Achieved at 28 Days Patients with Primary Composite Endpoint (%) bpm 70 to <75 bpm 65 to <70 bpm 60 to <65 bpm <60 bpm 0 0 D Time (months) Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22.
32 Effect of Ivabradine on Outcomes according to Magnitude of HR Reduction Patients with Primary Composite Endpoint (%) bpm 10 to <0 bpm > 10 bpm 0 0 D Time (months) Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22.
33 SHIFT Echo Substudy: Change in LVEF from Baseline to 8 mos (Secondary Endpoint) +2.7, p= Left Ventricular Ejection Fraction (%) ± ± ± ± 10.2 Ivabradine (n=204) 31.6 ± ± 10.0 Baseline 8 Months Baseline 8 Months Placebo (n=199) LVESVI = left ventricular end-systolic volume index. Tardif JC, et al. Eur Heart J. 2011;32(20):
34 Pooled Analysis of BEAUTIFUL and SHIFT Reduced EF, Heart Rate 75 bpm (N=7632) Fox K. Eur Heart J. 2013
35 FDA-Approved Ivabradine Ivabradine Brand name Indication Dosage Contraindications Side effects Corlanor To reduce the risk of hospitalization for worsening HF in patients with stable, symptomatic chronic HF with LVEF 35% who are in sinus rhythm with resting HR 70 bpm and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. Start with 5 mg twice daily. After 2 weeks of treatment, adjust dose based on HR. Max is 7.5 mg twice daily. In patients with conduction defects or in whom bradycardia could lead to hemodynamic compromise, start with 2.5 mg twice daily. Acute decompensated HF; BP <90/50 mmhg; sick sinus syndrome or third-degree AV block, unless a functioning demand pacemaker is present; resting HR < 60 bpm prior to treatment; severe hepatic impairment; pacemaker dependence. WARNING fetal toxicity. Occurring in 1% of patients are bradycardia, hypertension, atrial fibrillation, and luminous phenomena (phosphenes). Accessed October 20, 2015.
36 Practical Points on Use of Ivabradine Starting dose is 5 mg twice daily Target HR is bpm After 2 weeks: If HR >60 bpm: Increase dose to 7.5 mg twice daily (Max dose) If HR bpm: Maintain initial dose If HR <50 bpm or symptomatic bradycardia: Lower dose to 2.5 mg twice daily If HR <50 bpm or symptomatic bradycardia and dose is 2.5 mg twice daily: Discontinue
37 2016 ACC/AHA/HFSA Heart Failure Guideline Update Pharmacological Treatment for Stage C HFrEF COR = class of recommendation; LOE = level of evidence. Reference: Yancy et al. Circulation. 2016;134:[ePub ahead of print].
38 Potential Candidates for Ivabradine Therapy Patients with stable symptomatic chronic heart failure with LVEF 35% in sinus rhythm receiving standard therapy with resting heart rate 70 bpm Taking maximally tolerated doses of beta-blockers Common reasons for not taking maximally tolerated dose Hypotension CorlanorPrescribing Information, Amgen Fatigue Contraindicated to beta-blocker use Common reasons for not receiving any dose COPD Hypotension Severe Asthma
39 Updated from Fonarow GC, et al. Am Heart J 2011;161: Evidence-Based HFrEF Therapies Guideline Relative Risk Number Needed NNT for Mortality Relative Risk Recommended Reduction in to Treat for (standardized to Reduction in HF Therapy Mortality Mortality 36 months) Hospitalizations ACEI/ARB 17% 22 over 42 months 26 31% ARNI 16% 36 over 27 months 27 21% Beta-blocker 34% 28 over 12 months 9 41% Aldosterone Antagonist 30% 9 over 24 months 6 35% Hydralazine/Nitrate 43% 25 over 10 months 7 33% CRT 36% 12 over 24 months 8 52% ICD 23% 14 over 60 months 23 NA Ivabradine NA NA NA 26%
40 Potential Impact of Optimal Implementation of Evidence-Based HFrEF Therapies on Mortality Guideline Recommended HF Patient Current HF Potential Lives Potential Lives Therapy Population Population Saved per Year Saved per Year Eligible for Eligible and (Sensitivity Range*) Treatment, n* Untreated, n (%) ACEI/ARB 2,459, ,767 (20.4) 6516 ( ,260) Beta-blocker 2,512, ,809 (14.4) 12,922 ( ,329) Aldosterone Antagonist 603, ,326 (63.9) 21,407 (10,960-36,991) Hydralazine/Nitrate 150, ,749 (92.7) 6655 ( ,500) CRT 326, ,604 (61.2) 8317 ( ,372) ICD 1,725, ,512 (49.4) 12,179 ( ,045) Total ,996 (34, ,497) ARNI (replacing ACEI/ARB) 2,287,296 2,287,296 (100) 28,484 (18,230-41,017) Updated from Fonarow GC, et al. Am Heart J 2011;161: and JAMA Cardiology 2016
How Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs?
How Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs? Gregg C. Fonarow, MD FACC, FAHA, FHFSA Co-Chief UCLA Division of Cardiology Director, Ahmanson-UCLA
More informationNew Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD
New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD Professor of Medicine, Cell Biology, Radiology and Surgery Director, The Howard Gilman Institute for Heart Valve Disease and the Schiavone
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationRationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients
Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients Javed Butler, MD, MPH, MBA Patrick H. Lehan Professor of Medicine Professor of Physiology Chairman,
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationTrials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1
Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationNew Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition
New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition Prakash Deedwania, MD, FACC, FACP, FCCP, FAHA Professor of Medicine, UCSF School of Medicine, Director,
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationNew Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationTake-home Messages from Recent Heart Failure Trials: Heart Rate as a Target
Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target JEFFREY S. BORER, M.D. Professor and Chairman, Department of Medicine and Chief, Division of Cardiovascular Medicine; Director,
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationHeart Failure: Current Management Strategies
Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationCORLANOR (ivabradine) oral tablet
CORLANOR (ivabradine) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationHeart failure (HF) is a clinical syndrome with enormous relevance given its constantly. Benefits of early treatment with
A low percentage of patients achieve optimal β-blocker doses and optimal heart rate values with β-blocker administration. Ivabradine has been recognized not only for providing a prognostic benefit, but
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More informationΧριστίνα Χρυσοχόου Καρδιολόγος Επι,Α Καρδιολογική Κλινική Πανεπιστηίου Αθηνών, ΙΓΝΑ
Χριστίνα Χρυσοχόου Καρδιολόγος Επι,Α Καρδιολογική Κλινική Πανεπιστηίου Αθηνών, ΙΓΝΑ Digitalisis a genus of about 20 species of herbaceousperennials, shrubs, and biennialsthat are commonly called foxgloves.
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationPROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE
Press Release Issued on behalf of Servier Date: June 6, 2012 PROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE The new ESC guidelines for the diagnosis and
More informationSystolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine
Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More information12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices. Heart Rate as a Cardiovascular Biomarker
12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices Heart Rate as a Cardiovascular Biomarker Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine,
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More information9/10/ , American Heart Association 2
Clyde W. Yancy, MD, MSc, MACC, FAHA, MACP Vice Dean, Diversity & Inclusion Magerstadt Professor of Medicine Professor of Medical Social Sciences Chief, Division of Cardiology Northwestern University, Feinberg
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationIs Heart Rate a Treatment Target?
Is Heart Rate a Treatment Target? M. Böhm Innere Medizin III (Kardiologie / Angiologie / Internistische Intensivmedizin) Universitätsklinikum des Saarlandes Homburg/Saar michael.boehm@uks.eu Heart Rate
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationInitiating New Medications in the Management of Heart Failure
Initiating New Medications in the Management of Heart Failure Sandra Oliver-McNeil DNP, MSN, ACNP-BC, CHFN Associate Professor (Clinical) Wayne State University College of Nursing Objectives The participant
More informationHeart Failure Therapies State of the Art 2017
Heart Failure Therapies State of the Art 2017 Andrew J. Sauer, MD Assistant Professor Director, Center for Heart Failure Medical Director, Heart Transplantation UNOS Primary Transplant Physician asauer@kumc.edu
More information2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation
Effective Heart Failure Management through Evidence Based Practice and Innovation Jennifer Bauerly RN, CHFN, APRN-BC CentraCare Heart and Vascular Center Objectives Describe the scope and impact of heart
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationBurden of Mitral Regurgitation (MR) in the US Why is This Important?
Secondary (Functional) Mitral Regurgitation as a Target for Heart Failure Therapy William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP Professor of Medicine, Physiology, and Cell Biology Chair of Excellence
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationDisclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018
Disclosure Statement Heart Failure: Refreshers and Updates Tracy K. Pettinger, PharmD Clinical Associate Professor College of Pharmacy The planners and presenter of this presentation have disclosed no
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More informationCosa c è di nuovo nelle LLGG e nella gestione del paziente con scompenso cardiaco. Maurizio Volterrani IRCCS San Raffaele Rome Capri, 24 April 2015
Cosa c è di nuovo nelle LLGG e nella gestione del paziente con scompenso cardiaco Maurizio Volterrani IRCCS San Raffaele Rome Capri, 24 April 2015 Treatment options for patients with chronic symptomatic
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More information2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?
2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? Dr. Shelley Zieroth University of Manitoba @ShelleyZieroth @CanHFSociety Disclosures Consulting/Advisory Board: Amgen, Astra
More informationEvidence of Baroreflex Activation Therapy s Mechanism of Action
Evidence of Baroreflex Activation Therapy s Mechanism of Action Edoardo Gronda, MD, FESC Heart Failure Research Center IRCCS MultiMedica Cardiovascular Department Sesto S. Giovanni (Milano) Italy Agenda
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationHeart Failure Medications: Who Needs What Drug Now? Disclosures
Heart Failure Medications: Who Needs What Drug Now? Simon Jackson MD FRCPC MMedEd Professor of Medicine (Cardiology) Dalhousie 1 Disclosures Honoraria and educational grants from: Actelion (medications
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationClinical Pearls Heart Failure Cardiology/New Drugs
Clinical Pearls Heart Failure Cardiology/New Drugs Friday, September 9 th, 2016 Heidi Burres, PharmD, BCACP MTM Pharmacist Fairview Pharmacy Services Thank You to XYZ Event Sponsor(s): Wi-fi Information:
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationNew Drug Evaluation: ivabradine tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More information2/15/2017. Disclosures. Heart Failure = Big Problem. Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017
Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017 Julio A. Barcena, M.D. South Miami Heart Specialists Disclosures I have no relevant commercial relationships to
More informationImplementing the CardioMEMS HF System into the Management of Heart Failure Patients
Implementing the CardioMEMS HF System into the Management of Heart Failure Patients Robert W. Hull MD FACC Associate Professor of Medicine WVU Heart Institute Co-director, Arrhythmia Service Director,
More informationCorlanor. Corlanor (ivabradine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.05 Subject: Corlanor Page: 1 of 5 Last Review Date: June 24, 2016 Corlanor Description Corlanor (ivabradine)
More informationWhat s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA
What s new in the 2017 heart failure guidelines Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA Key points to remember 2017 guidelines recommend using natriuretic peptides as biomarkers to screen for heart
More informationHeart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none
Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying
More informationHeart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA
Heart Failure with Reduced EF Dino Recchia, MD, FACC, FHFSA Heart Failure HF is the end phenotype of almost all CV disorders Complex clinical syndrome resulting from any structural or functional impairment
More informationMedical management of AF: drugs for rate and rhythm control
Medical management of AF: drugs for rate and rhythm control Adel Khalifa Sultan Hamad, BMS, MD, FGHRS, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist Head of Electrophysiology
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationCardiovascular Pharmacotherapy for Heart Failure Management
Cardiovascular Pharmacotherapy for Heart Failure Management AN UPDATE OF THE LATEST RECOMMENDATIONS AND DATA By: Debby Caraballo, PharmD, PhC, BCPS, AQ-Cardiology Balloon Fiesta Symposium, Albuquerque,
More informationFINANCIAL DISCLOSURE: No relevant financial relationship exists
The Value of Guideline Directed Medical Therapy in Heart Failure Steve Dentel RN BSN CPHQ National Director, Field Programs and Integration American Heart Association/American Stroke Association FINANCIAL
More informationThe role of remote monitoring in preventing readmissions after acute heart failure
The role of remote monitoring in preventing readmissions after acute heart failure October 20, 2017 Randall C Starling MD MPH FACC FAHA FESA FHFSA Professor of Medicine Kaufman Center for Heart Failure
More informationSacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC
Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC Head of Cardiology Medical Manager / CV Program CHUM Disclosure Statement Within the past two years: I have had an
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationOptimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists
Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Old Drugs for an Old Problem Jay Geoghagan, MD, FACC BHHI Primary Care Symposium February 28, 2014 None. Financial disclosures
More informationNew Drug Evaluation: ivabradine tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information